# Leaderna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leaderna-therapeutics

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Total disclosed funding: $22M
- Latest round: Series A (Aug 31, 2026)
- Investors on record: 11

## About

Based in Sichuan, China, and founded in 2022, Leaderna Therapeutics Ltd., trading as Leaderna Therapeutics, provides synthetic oligonucleotide drug research and development for the biotechnology industry. The company operates a full chain platform covering target validation, lead compound screening, and formulation development. The chairman and general manager is Dr. Jinqiao Wan. In August 2026, Leaderna Therapeutics raised a Series A+ funding from GTJA Investment Group.

The company works with the healthcare sector to provide innovative therapies for chronic diseases. A team of researchers and scientists develops small nucleic acid drugs utilizing proprietary technology platforms such as NEATL (novel delivery and nucleic acid enhancement), LOCATED (lipid-conjugated extrahepatic delivery), and DIRECT (single-molecule dual target interference).

The company generates revenue from the research, development, and commercialization of its small nucleic acid drugs.

The Series A+ funding raised in August 2026 will primarily be used to promote the clinical development of its world-first small nucleic acid product pipeline, accelerate the optimization of key technology platforms such as extrahepatic delivery, and further expand its preclinical product portfolio.

## Funding rounds

- Series A, Aug 31, 2026 — GTJA Investment Group
- Series A, Mar 20, 2026, $22M — Chengdu Science and Technology Venture Capital Group, Caleb Capital, Tao Capital, Hi-tech VC, Huaige Capital, Qishen Venture Capital, Juntian Venture Capital, Lhasa Huabo Health Development Co., Ltd, HitGen, Yinman Fund

## Investors

- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series A
- Caleb Capital — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A
- Hi-tech VC (https://capitalatlas.ai/funds/hi-tech-vc) — Series A
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series A
- Qishen Venture Capital — Series A
- Juntian Venture Capital — Series A
- Lhasa Huabo Health Development Co., Ltd — Series A
- HitGen — Series A
- Yinman Fund — Series A
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A